Singapore markets open in 2 hours 28 minutes

TScan Therapeutics, Inc. (TCRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.13-0.56 (-7.28%)
At close: 04:00PM EDT
7.27 +0.14 (+1.96%)
After hours: 06:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.69
Open7.50
Bid7.13 x 100
Ask7.21 x 100
Day's range7.12 - 7.55
52-week range1.62 - 9.00
Volume98,698
Avg. volume164,538
Market cap341.561M
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

    WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase share

  • GlobeNewswire

    TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

    Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy Patients identified across all six TCR-T cohorts in solid tumor program with dosing of first three expected in early May All eight patients in the heme program treated with TSC-100 or TSC-101 remain relapse-free with no detectable cancer to date; median follow-up of >10 months WALTHAM, Mass

  • GlobeNewswire

    TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

    Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial developmentWALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extens